New Delhi, July 31 -- Sun Pharmaceutical Industries, India's largest drugmaker market capitalization, missed Street expectations in the June quarter as weakness in its US generics business weighed on profitability despite double-digit revenue growth and continued strength in its India and innovative medicines businesses.

The company reported consolidated revenue of Rs.15,299 crore for the June quarter, up 10.5% year-on-year, while net profit rose 27% to Rs.2,895 crore. Strong growth in the domestic business and innovative medicines offset a decline in US generics sales but was not enough to meet analyst estimates.

A Bloomberg poll had pegged revenue at Rs.15,527 crore and net profit at Rs.2,974 crore.

Adjusted net profit rose 3.1% to R...